EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer

Etienne J Slapak iD, Mouad El Mandili, Marieke S Ten Brink, Alexander Kros iD, Maarten F Bijlsma iD, C Arnold Spek iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241310704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Etienne J Slapak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC Location University of Amsterdam,…. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society, Dutch Cancer Foundation (KWF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic adenocarcinoma (PDAC) remains largely refractory to chemotherapeutic treatment regimens and, consequently, has the worst survival rate of all cancers. The low efficacy of current treatments results largely from toxicity-dependent dose limitations and premature cessation of therapy. Recently, targeted delivery approaches that may reduce off-target toxicities have been developed. In this paper, we present a preclinical evaluation of a PDAC-specific drug delivery system based on mesoporous silica nanoparticles (MSNs) functionalized with a protease linker that is specifically cleaved by PDAC cells. Our previous work demonstrated that ADAM9 is a PDAC-enriched protease and that paclitaxel-loaded ADAM9-responsive MSNs effectively kill PDAC cells in vitro. Here, we show that paclitaxel-loaded ADAM9-MSNs result in off-target cytotoxicity in clinically relevant models, which spurred the development of optimized ADAM9-responsive MSNs (OPT-MSNs). We found that these OPT-MSNs still efficiently kill PDAC cells but, as opposed to free paclitaxel, do not induce death in neuronal or bone marrow cells. In line with these in vitro data, paclitaxel-loaded OPT-MSNs showed reduced organ damage and leukopenia in a preclinical PDAC xenograft model. However, no antitumor response was observed upon OPT-MSN administration in vivo. The poor in vivo antitumor activity of OPT-MSNs despite efficient antitumor effects in vitro highlights that although MSN-based tumor-targeting strategies may hold therapeutic potential, clinical translation does not seem as straightforward as anticipated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaPancreatic NeoplasmsNanoparticlesHumansDoxorubicinSilicon DioxideDrug Delivery SystemsPaclitaxelPeptide HydrolasesPorosityDrug CarriersMembrane ProteinsADAM Proteins

Stichwörter der Autor:innen

MSNPDACantitumordrug deliveryleukopenianeurotoxicitytargeted therapy

Substanzen

DoxorubicinSilicon DioxidePaclitaxelPeptide HydrolasesDrug CarriersADAM9 protein, humanMembrane ProteinsADAM Proteins

Autor:innen und Institutionen

  • Laboratory of Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
  • Oncode Institute, 3521 AZ Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Cancer Biology, 1081 HV Amsterdam, The Netherlands.
  • Department of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, 2333 CC Leiden, The Netherlands.

ORCID-Profile: Etienne J Slapak, Alexander Kros, Maarten F Bijlsma, C Arnold Spek

Förderung

  • Dutch Cancer Society
  • Dutch Cancer Foundation (KWF)

Zitieren

APA

Slapak, E. J., El Mandili, M., Brink, M. S. T., Kros, A., Bijlsma, M. F., & Spek, C. A. (2023). Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310704

Vancouver

Slapak EJ, El Mandili M, Brink MST, Kros A, Bijlsma MF, Spek CA. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310704

BibTeX
@article{Slapak2023,
  author = {Slapak, Etienne J and El Mandili, Mouad and Brink, Marieke S Ten and Kros, Alexander and Bijlsma, Maarten F and Spek, C Arnold},
  title = {Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241310704}
}
Kostenlos starten →